Full side-by-side comparison — 2026
Data as of May 20, 2026 · Updated automatically
| Metric | JNJ | KO |
|---|---|---|
| Current Price | 230.48 | 81.18 |
| Previous Close | 229.32 | 81.55 |
| Metric | JNJ | KO |
|---|---|---|
| Trailing P/E | 26.24 | 25.42 |
| Forward P/E | 17.84 | 23.20 |
| Price / Book | 6.72 | 10.34 |
| Price / Sales | 5.66 | 7.06 |
| EV / EBITDA | 16.86 | 22.77 |
| Metric | JNJ | KO |
|---|---|---|
| Dividend Yield | 0.0229% | 0.0254% |
| Dividend Rate (Annual) | 5.20 | 2.06 |
| 5-Year Avg Yield | 2.77% | 2.99% |
| Payout Ratio | 0.5952% | 0.8007% |
| Metric | JNJ | KO |
|---|---|---|
| Beta (Volatility) | 0.26 | 0.36 |
| Debt / Equity | 67.73 | 124.94 |
| Quick Ratio | 0.69 | 0.78 |
| Current Ratio | 1.03 | 1.36 |
| Metric | JNJ | KO |
|---|---|---|
| Revenue Growth | 0.0990% | 0.1210% |
| Earnings Growth | -0.5290% | 0.1820% |
| Return on Equity | 0.2642% | 0.4337% |
| Revenue / Share | 40.02 | 11.45 |
| Trailing EPS | 8.64 | 3.18 |
| Forward EPS | 12.71 | 3.48 |
| Metric | JNJ | KO |
|---|---|---|
| Analyst Mean Target | 252.96 | 85.71 |
| Analyst High Target | 285.00 | 92.00 |
| Analyst Low Target | 155.00 | 71.38 |
Johnson & Johnson (JNJ) leads on 11 of 19 comparable metrics.
Johnson & Johnson is the stronger pick for value investors, while The Coca-Cola Company may appeal to income investors.
This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.
JNJ's earnings declined 53% — declining profits may mean current valuation metrics (PE, payout ratio) are misleading.
Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in …
View JNJ details →The Coca-Cola Company, a beverage company, manufactures and sells various nonalcoholic beverages in the United States and internationally. The company provides Trademark Coca-Cola, sparkling soft drinks and flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and emerging beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers comprising restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, …
View KO details →Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.
Start Free Portfolio